Business
UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness
Company to Also Participate in September Investor Conferences NEW YORK--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\nCompany to Also Participate in September Investor Conferences\n\n NEW YORK--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will host an Investor Day on September 24, 2019 in New York where the Company will share updates on its clinical programs and launch readiness plans for UGN-101 (mitomycin gel) for instillation, its lead product candidate for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). The program will also highlight the Company’s vision and strategy and include a panel discussion with key opinion leaders on the treatment of LG UTUC and low-grade non-muscle invasive bladder cancer.\n\n\nThe live audio webcast and accompanying slide presentation will begin at 10:00AM Eastern Time. The live audio webcast can be accessed through the Events and Presentations section under the Investors tab of UroGen’s website at www.urogen.com. Following the live audio webcast, a replay will be available on UroGen’s website for approximately 30 days.\n\n\nManagement will also present at two investor conferences in September:\n\n\nH.C. Wainwright 21st Annual Global Investment Conference \n\n\n\nTuesday, September 10th\n\n\n10:50AM Eastern Time\n\n\nNew York, NY\n\n\n\nLadenburg Thalmann Healthcare Conference\n\n\n\nTuesday, September 24th\n\n\n3:00PM Eastern Time\n\n\nNew York, NY\n\n\n\nA live audio webcast of each event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.\n\n\nAbout UroGen Pharma Ltd. \n\n\nUroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillatio...